This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abbott Labs Inks $1.35 Billion Biotech Deal

The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.

NEW YORK ( Trefis) -- Abbott Labs (ABT) recently announced a $1.35 billion deal with Belgian drug developer Galapagos to develop and commercialize an oral JAK1 inhibitor in Phase II development to treat autoimmune diseases, including rheumatoid arthritis.

The company has also entered a deal with University of North Texas science center for human identification testing. The deals will strengthen Abbott's foothold in autoimmune and diagnostics market. Our price estimate for Abbott Labs stands at $62, implying a premium of about 10% to the current market price.

See Full Analysis for Abbott Labs here.

Abbott's Humira, one of the world's largest selling drugs and a leader for treatment of rheumatoid arthritis, is likely to face competition from other oral JAK inhibitors including Pfizer's tofacitinib, if they manage to get U.S. regulatory approvals. Humira is a TNF inhibitor and is injected in the body.

In addition, Humira with lose its U. S. patent protection at the end of 2016. The collaboration will give Abbott a channel fend off new entrants and help it retain its market leader position in autoimmune market.

The autoimmune segment constitutes nearly 20% of our price estimate for the company. Accordingly, any substantial progress towards development of new oral JAK1 inhibitor drug could impact our estimate of the company's value.

Abbott will have to shell out approximately $1.35 billion including an initial payment of $150 million for the global rights. Upon the successful completion of the Phase II studies and meeting certain pre-agreed criteria, Abbott will license the drug for $200 million and will take responsibility of further testing and development.

Galapagos would also be eligible to receive additional milestone payments up to $1 billion in addition to tiered double-digit royalties on net sales, once the drug receives final regulatory approvals and upon commercialization. However, Galapagos will retain co-promotion rights in Belgium, the Netherlands and Luxembourg.

The company has entered into an agreement with the University of North Texas Science Center, one of the leading forensics institutions, to evaluate and promote the company's PLEX-ID instrument for use in analyzing human remains to support missing persons and human trafficking investigations. The collaboration may help Abbott strengthen its position in molecular and in-vitro diagnostics market.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $115.02 -2.90%
FB $94.46 0.34%
GOOG $629.88 -0.21%
TSLA $263.53 1.40%
YHOO $37.01 0.87%

Markets

Chart of I:DJI
DOW 17,594.62 -3.58 -0.02%
S&P 500 2,097.04 -1.00 -0.05%
NASDAQ 5,107.1380 -8.2440 -0.16%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs